TI
KALV

Telemetry Investments’s KalVista Pharmaceuticals KALV Stock Holding History

Telemetry Investments’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-24,883
Closed -$491K – 131
2018
Q4 		$491K Buy
24,883
+8,883
+56% +$179K 0.31% 76
2018
Q3 		$354K Sell
16,000
-39,104
-71% -$529K 0.16% 74
2018
Q2 		$447K Buy
+55,104
New +$486K 0.17% 65

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Telemetry Investments's KALV Position: Q1 2019 in Review

Telemetry Investments sold out of KalVista Pharmaceuticals (KALV) in Q1 2019, closing a stake of 24,883 shares — an estimated $491K sold.

Telemetry Investments first reported a position in KALV in Q2 2018 and held it in 3 quarters. The position peaked at $491K in Q4 2018. 68 funds tracked by Wall St. Rank hold KALV as of Q1 2019.

  • Telemetry Investments reported no remaining KalVista Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Telemetry Investments sold 24,883 KalVista Pharmaceuticals shares in Q1 2019, an estimated $491K.
  • Telemetry Investments first reported a position in KalVista Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Telemetry Investments's KalVista Pharmaceuticals position peaked at $491K in Q4 2018.
  • 68 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2019.

Based on Telemetry Investments's 13F filing for Q1 2019, filed 15 May 2019.